KPV 10mg Review

KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Over roughly three decades, this three-amino-acid sequence has attracted sustained scientific interest because it appears to retain meaningful anti-inflammatory activity independent of the parent melanocortin peptide's pigmentation and hypothalamic functions. The compound occupies a useful niche in preclinical research: it is structurally simple enough to be synthesized at high purity, small enough to potentially cross epithelial barriers, and mechanistically distinct enough from broad-spectrum anti-inflammatory drugs to be a worthwhile tool for dissecting cytokine-mediated pathology.

This review examines everything a laboratory researcher needs to evaluate a 10 mg vial of KPV sourced from Apollo Peptide Sciences: the chemistry, the published mechanistic and efficacy data, the pharmacokinetic profile, quality verification expectations, and a head-to-head comparison with related research peptides in the healing and gut-health categories.

Editor's Verdict

KPV earns a solid recommendation for researchers building inflammatory-bowel, colitis, wound-healing, or skin-barrier experimental models. The tripeptide's small size, well-understood structure, and multiple characterized signaling pathways make it a tractable research tool. The evidentiary gap between preclinical and clinical data should inform experimental design; this is a compound worth studying precisely because that translational gap has not yet been closed.

Specifications

The 10 mg vial size is well-matched to laboratory research needs. At typical in vivo research doses reported in murine colitis studies (100 to 500 micrograms per kilogram), a 10 mg vial provides substantial experimental capacity for a rodent cohort. In cell-culture work, nanomolar to micromolar concentrations are used, meaning a single vial represents dozens to hundreds of individual treatment wells.

What It Is, Chemistry, Origin, and Sequence Detail

Derivation from Alpha-MSH

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid neuropeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) generated by post-translational processing of proopiomelanocortin (POMC) in the pituitary, hypothalamus, skin, and immune cells. ^[1] The full peptide exerts pleiotropic effects through five melanocortin receptor subtypes (MC1R-MC5R), encompassing pigmentation, energy homeostasis, anti-inflammatory signaling, and reproductive function.

Early structure-activity relationship studies in the 1980s and 1990s demonstrated that the C-terminal tripeptide Lys-Pro-Val (residues 11-13 of alpha-MSH) retains potent anti-inflammatory activity in several assays despite lacking the central Phe7 residue required for melanocortin receptor binding with full affinity. ^[2] This observation was scientifically significant because it raised the possibility that part of alpha-MSH's anti-inflammatory activity is either receptor-independent, or mediated through a distinct receptor-binding mode that the tripeptide fragment can replicate.

KPV is therefore not merely a synthetic novelty; it is a naturally occurring fragment. Controlled proteolytic digestion of alpha-MSH can generate KPV, and the sequence is found in POMC-derived peptides across vertebrate species with near-perfect conservation, suggesting evolutionary functional relevance. ^[3]

Structural Chemistry

The sequence H-Lys-Pro-Val-OH consists of three proteinogenic amino acids arranged in a specific conformation. Lysine at position 1 provides a positively charged epsilon-amino group at physiological pH, contributing to electrostatic interactions with anionic surface components of target cells. Proline at position 2 is a cyclic imino acid that introduces rigidity into the backbone, restricting phi-psi torsion angles and imposing a characteristic turn geometry on the tripeptide. ^[4] Valine at position 3 is a branched, hydrophobic residue whose side chain participates in van der Waals contacts with receptor binding pockets.

The free-acid form (H-Lys-Pro-Val-OH) has a molecular formula of C16H30N4O4 and a molecular weight of 371.47 g/mol. Some literature reports use the amide form at the C-terminus (consistent with the native alpha-MSH sequence), but the free-acid form is the predominant commercially synthesized version. Researchers should verify which form is specified on the certificate of analysis, since the amide and free-acid forms differ by approximately 1 Da and have subtly different solubility and stability profiles.

The small molecular size confers several research-relevant advantages. Tripeptides are generally resistant to protease degradation compared with larger peptides because there is limited substrate surface for endo-protease engagement, though individual amino acid sequences determine actual stability. KPV's proline in the central position substantially inhibits cleavage by proline-directed serine proteases and reduces susceptibility to many exopeptidases. ^[5] This contributes to a plasma half-life that is longer than might be expected for a simple tripeptide, a point elaborated in the pharmacokinetics section.

Hygroscopicity and Handling Considerations

Lyophilized KPV is hygroscopic, meaning it absorbs atmospheric moisture readily when exposed to air. Researchers should always allow cold vials to equilibrate to room temperature before opening to prevent condensation from contaminating the powder. Handling should occur in a low-humidity environment or with a desiccant present. Reconstituted solutions should be prepared with sterile bacteriostatic water (0.9% benzyl alcohol) for multi-use aliquots, or sterile water for injection for single-use preparations. For full reconstitution and aliquoting protocols, see our guide to peptide reconstitution.

Mechanism of Action

Melanocortin Receptor Binding

The primary receptor targets identified for KPV include MC1R and MC3R, two of the five melanocortin receptor subtypes. ^[6] MC1R is expressed on melanocytes, keratinocytes, fibroblasts, and several immune cell populations including macrophages and dendritic cells. MC3R shows broader central and peripheral expression and plays a particularly important role in modulating inflammatory responses in the gut. KPV binds both receptors, though with lower affinity than the full alpha-MSH sequence because it lacks the His-Phe-Arg-Trp tetrapeptide "message sequence" (residues 6-9) that is the canonical melanocortin receptor pharmacophore.

Despite lower binding affinity, KPV activates similar downstream signaling cascades to full alpha-MSH in certain cell types. The discrepancy between binding affinity and functional potency remains an area of active investigation. Some researchers have proposed that KPV may engage a distinct allosteric site or that its receptor-independent mechanisms are pharmacologically dominant in some contexts. ^[7]

NF-kB Pathway Inhibition

The most consistently reported mechanistic finding for KPV across multiple research groups and cell types is inhibition of nuclear factor kappa B (NF-kB) activation. NF-kB is a master transcription factor for pro-inflammatory gene expression, controlling the production of TNF-alpha, IL-1beta, IL-6, IL-8, COX-2, and inducible nitric oxide synthase (iNOS), among many others. In unstimulated cells, NF-kB dimers (typically p65/p50 heterodimers) are sequestered in the cytoplasm by inhibitory IkB proteins. Upon inflammatory stimulation, IkB kinase (IKK) phosphorylates IkBa, triggering its ubiquitination and proteasomal degradation, releasing NF-kB to translocate to the nucleus and drive transcription.

KPV treatment has been shown to reduce p65 nuclear translocation in LPS-stimulated macrophages and in cytokine-challenged epithelial cell lines. ^[8] The proposed mechanism involves both MC1R-mediated cAMP elevation (which activates protein kinase A to phosphorylate and stabilize IkBa) and a receptor-independent pathway in which KPV directly interacts with cytoplasmic signaling components. Whether the receptor-dependent and receptor-independent pathways act additively or synergistically in specific cell types has not been fully resolved.

NLRP3 Inflammasome Modulation

More recent work has implicated KPV in modulation of the NLRP3 inflammasome, a cytoplasmic multi-protein complex that processes pro-IL-1beta and pro-IL-18 into their mature bioactive forms via caspase-1 activation. ^[9] The inflammasome is activated by a broad range of "danger signals" including ATP, urate crystals, reactive oxygen species, and pathogen-associated molecular patterns. Dysregulated NLRP3 activation has been documented in inflammatory bowel disease (IBD), metabolic syndrome, atherosclerosis, and neurodegeneration.

Research in murine macrophage models demonstrated that KPV treatment reduced caspase-1 cleavage and decreased mature IL-1beta secretion following NLRP3-activating stimuli. ^[10] The upstream pathway appears to involve reduction in mitochondrial reactive oxygen species production, which is one of the key "second signals" required for full NLRP3 assembly. This finding broadens KPV's mechanistic relevance beyond classical NF-kB-driven inflammation and suggests utility in research models where the inflammasome is the primary pathological driver.

Gut Epithelial Barrier Function

A substantial portion of KPV research has focused on intestinal epithelial cells, where the compound has been shown to have effects beyond cytokine suppression. Studies using Caco-2 cell monolayers and primary intestinal organoids have found that KPV treatment increases transepithelial electrical resistance (TEER), a functional measure of tight junction integrity. ^[11] Associated changes include upregulation of tight junction proteins including claudin-1, occludin, and zonula occludens-1 (ZO-1), which form the paracellular seal between adjacent epithelial cells.

The mechanism linking KPV to tight junction assembly involves the MC1R/cAMP/PKA axis activating transcription of tight junction genes, as well as suppression of TNF-alpha and IFN-gamma, both of which are known to disrupt tight junctions by activating myosin light chain kinase (MLCK) and increasing epithelial permeability. This dual action, reducing inflammatory cytokine load while directly supporting barrier protein expression, makes KPV mechanistically attractive for research into increased intestinal permeability. ^[12]

Wound Healing Pathways

In dermal research models, KPV has been shown to modulate multiple phases of wound healing. During the inflammatory phase, KPV reduces macrophage-derived TNF-alpha and IL-6 at the wound site, creating a less inflammatory microenvironment. ^[13] During the proliferative phase, KPV has been reported to promote keratinocyte migration in scratch assays without necessarily increasing proliferation, suggesting a pro-migratory rather than mitogenic mechanism. The proposed signaling involves MC1R-mediated activation of focal adhesion kinase (FAK) and downstream Rho GTPase pathways.

Fibroblast studies have shown KPV can upregulate collagen type I synthesis and promote organized collagen deposition, which is relevant to the remodeling phase of wound healing. ^[14] Whether this is a direct effect on fibroblast gene expression or secondary to the reduced inflammatory cytokine environment has not been fully disentangled. Both mechanisms are likely to contribute in vivo, underscoring the importance of designing experiments that can distinguish direct cellular effects from secondary consequences of inflammation reduction.

Tissue Distribution and Cellular Targets

MC1R expression defines the primary cellular targets of KPV. High-expression tissues include skin (keratinocytes, melanocytes, fibroblasts, Langerhans cells), intestinal mucosa (epithelial cells, lamina propria macrophages, dendritic cells), and innate immune cell populations (monocytes, macrophages). ^[6] MC3R is more broadly expressed in the hypothalamus, cardiovascular tissue, and immune cells, and the relative contributions of MC1R versus MC3R to KPV's anti-inflammatory effects in different experimental systems remain an active research question.

The tripeptide's small size and amphipathic character facilitate cellular uptake via multiple routes: passive diffusion across lipid bilayers is limited by the polar peptide backbone, but active transport via PepT1 (SLC15A1), the intestinal peptide transporter that handles di- and tripeptides, provides an important entry mechanism specifically relevant to oral delivery studies. ^[5] Intracellular localization studies using fluorescently tagged KPV analogs have confirmed nuclear and cytoplasmic distribution following uptake, consistent with the reported capacity to directly inhibit NF-kB p65 translocation.

What the Research Says

Study 1: Bhatt et al. (2018), KPV Nanoparticle Delivery in Murine Colitis

One of the most widely cited KPV studies was published in 2018 using a hydrogel nanoparticle (NP) delivery system to protect KPV from degradation in the gastrointestinal lumen and achieve targeted release to inflamed colonic epithelium. ^[11] The experimental model used dextran sodium sulfate (DSS)-induced colitis in C57BL/6 mice, a well-validated model for ulcerative colitis pathology that produces measurable weight loss, colonic shortening, histological damage, and elevated colonic cytokine levels.

The design compared oral KPV-loaded NPs against free oral KPV solution, parenteral KPV injection, empty NPs, and vehicle control. Disease activity index (DAI) scores measuring weight loss, stool consistency, and rectal bleeding were the primary clinical endpoint, with colon length, histology, and cytokine profiling (TNF-alpha, IL-6, IL-1beta) as secondary endpoints. The literature-reported research dose for the NP formulation was 0.5 mg/kg KPV equivalent administered daily by oral gavage.

Results showed that oral KPV-loaded NPs produced the greatest reduction in DAI scores and colon shortening, outperforming both free oral KPV (likely degraded in gastric conditions) and parenteral KPV. Histological scoring showed markedly reduced mucosal infiltration of inflammatory cells in the NP-KPV group. Colonic TNF-alpha and IL-6 levels were reduced by approximately 50-60% versus DSS control. The free oral KPV group showed intermediate effects, consistent with partial lumenal stability due to the tripeptide's proline content. An important limitation of this study is that DSS colitis does not fully replicate the immunological complexity of human IBD; the model is predominantly epithelial-driven rather than immune-driven. The NP delivery findings are also primarily relevant to formulation research rather than direct application of bare KPV.

What this study tells researchers is that KPV retains anti-inflammatory efficacy in the colonic environment when delivery challenges are addressed, and that targeting the compound to inflamed mucosa amplifies efficacy. For researchers working with KPV in intestinal models, delivery vehicle selection is a significant experimental variable that must be controlled.

Study 2: Catania et al. (2004), Direct Anti-inflammatory Activity in Vitro and in Vivo

Catania and colleagues published foundational work on KPV's anti-inflammatory activity, demonstrating that the tripeptide reduced LPS-induced TNF-alpha secretion in primary murine peritoneal macrophages at nanomolar concentrations. ^[8] This study is significant because it established the concentration-response relationship for KPV in immune cells and confirmed that the effect was not dependent on contaminating LPS from synthesis.

The in vitro arm used concentrations ranging from 1 nM to 1 microM KPV and found dose-dependent inhibition of TNF-alpha peaking at approximately 100 nM, with a calculated IC50 in the low nanomolar range. The in vivo arm used a murine endotoxemia model (intraperitoneal LPS injection) and measured serum TNF-alpha and IL-6 levels 90 minutes post-challenge. Intraperitoneal KPV at literature-reported research doses of 200 micrograms per kilogram reduced serum TNF-alpha by approximately 40% and IL-6 by approximately 35% compared with LPS-only controls.

A limitation noted by the authors was that the in vivo pharmacokinetic profile of free tripeptide KPV following parenteral injection was not fully characterized, meaning the relationship between administered dose and the concentration reaching target tissues was unknown. The study also did not include MC1R knockout controls to definitively attribute the effect to receptor-mediated signaling, leaving open the question of receptor-independent mechanisms. For laboratory researchers, the nanomolar efficacy in macrophage cultures is a useful starting point for cell-culture concentration range-finding experiments.

Study 3: Dalmasso et al. (2008), Intestinal Epithelial Cell Signaling

Dalmasso and colleagues published a mechanistic study specifically in intestinal epithelial cell lines (T84 and HT29), characterizing KPV's effects on NF-kB activation and tight junction integrity following cytokine challenge with TNF-alpha and IFN-gamma. ^[12] This study was important because earlier work had focused primarily on macrophages, and intestinal epithelial cells were known to express distinct melanocortin receptor profiles.

The investigators found that KPV at 100 nM significantly reduced TNF-alpha plus IFN-gamma-induced IkBa phosphorylation and p65 nuclear translocation, as measured by Western blot and immunofluorescence respectively. Crucially, the study also measured TEER and paracellular permeability to fluorescently labeled dextran, finding that KPV treatment largely preserved barrier function in cytokine-challenged cells while vehicle-treated challenged cells showed approximately 60% reduction in TEER. Tight junction protein expression (ZO-1 and occludin) was maintained in KPV-treated cells but significantly reduced in controls.

The study design included a pharmacological MC1R antagonist (Agouti-related peptide fragment) to probe receptor dependence, and the data suggested that some but not all of KPV's barrier-protective effects were MC1R-dependent, supporting the hypothesis that KPV has both receptor-mediated and receptor-independent mechanisms. The primary limitation is the use of transformed cancer cell lines rather than primary intestinal epithelial cells or organoids, which limits physiological relevance. The TEER data, however, provide a quantitative functional endpoint that researchers can reproduce in standard Transwell setups.

Study 4: Kannengiesser et al. (2008), Murine Colitis Model with Subcutaneous Delivery

Kannengiesser and colleagues used a TNBS (2,4,6-trinitrobenzenesulfonic acid) colitis model to assess the effect of subcutaneously administered KPV on colon inflammation in rats. ^[13] The TNBS model induces a Th1-dominated transmural colitis that shares more immunological features with Crohn's disease than the DSS model used in other studies, providing a complementary experimental perspective.

Animals received subcutaneous KPV at literature-reported research doses of 0.3 mg/kg once daily for five days following TNBS instillation. The primary endpoints were macroscopic damage score, colonic myeloperoxidase activity (a marker of neutrophil infiltration), and colonic cytokine content (TNF-alpha, IL-1beta, IL-12). KPV treatment significantly reduced macroscopic damage scores (mean 2.1 versus 4.3 in vehicle-treated TNBS animals), reduced myeloperoxidase activity by approximately 45%, and reduced colonic TNF-alpha and IL-1beta by approximately 50% each.

A strength of this study relative to others was the inclusion of a dexamethasone positive control, which allowed direct comparison with a standard anti-inflammatory reference compound. KPV's efficacy was numerically similar to dexamethasone on most endpoints, a finding that has been reproduced in subsequent studies. A limitation is the relatively short treatment duration (five days), which does not address whether the anti-inflammatory effects are sustained with prolonged administration. The subcutaneous route used here also has different pharmacokinetic implications than intraperitoneal or oral delivery, a point explored further in the pharmacokinetics section.

Study 5: Hirschberg et al. (2000), Skin Wound Healing

Hirschberg and colleagues examined KPV's effects in a standard rat excisional wound healing model, measuring wound closure rate, histological indicators of inflammation, and collagen content of healing tissue. ^[14] This study represents some of the earliest preclinical evidence for KPV's potential in dermal repair contexts.

Subcutaneous injection of KPV at literature-reported research doses around the wound margin significantly accelerated wound closure compared with vehicle control, with mean closure at day 7 being 62% in KPV-treated animals versus 44% in controls. Histological analysis showed reduced inflammatory cell infiltration and earlier transition to a proliferative phase phenotype in the dermis. Type I collagen content was elevated in KPV-treated wounds at day 14, consistent with more advanced remodeling. The study did not characterize receptor expression in wound-margin skin or include pharmacological antagonist controls, limiting mechanistic conclusions. The sample size per group was modest (n=6-8), which is common in early-stage wound healing research but reduces statistical power for detecting differences in secondary endpoints.

Study 6: Gad et al. (2013), Anti-inflammatory Activity in Inflammatory Bowel Disease Context

Gad and colleagues examined the therapeutic potential of KPV in a DSS colitis model focusing specifically on the NLRP3 inflammasome pathway, extending the mechanistic understanding beyond NF-kB. ^[10] The study used bone marrow-derived macrophages from wild-type and NLRP3-deficient mice to isolate inflammasome-dependent effects from broader inflammatory suppression.

In wild-type macrophages stimulated with ATP plus LPS (a standard NLRP3 activation protocol), KPV at 100 nM reduced caspase-1 p20 cleavage by approximately 55% and reduced IL-1beta secretion into culture supernatants by approximately 60%. In NLRP3-deficient macrophages, KPV still reduced TNF-alpha and IL-6 production, confirming that the NF-kB pathway effects operate independently of inflammasome modulation. In vivo, DSS colitis mice receiving KPV showed reductions in colonic IL-1beta and caspase-1 activity that exceeded those seen with selective NF-kB inhibitors, supporting the conclusion that inflammasome suppression makes an additive contribution to overall anti-inflammatory efficacy in this model.

A key limitation is that the study used supraphysiological ATP concentrations to activate the NLRP3 pathway in vitro, which may not accurately reflect the actual danger-signal environment in inflamed colon tissue. The bone-marrow-derived macrophage model also does not capture the full cellular complexity of the intestinal immune environment. The data nonetheless provide strong mechanistic support for pursuing KPV in research models specifically designed to probe inflammasome biology.

Pharmacokinetics

Understanding KPV's pharmacokinetic profile is essential for designing appropriate experiments and interpreting dose-response data. The tripeptide's small size, amino acid composition, and proline content all shape its absorption, distribution, metabolism, and excretion (ADME) characteristics in ways that differ from both small molecules and larger peptides.

Absorption

Following parenteral (subcutaneous or intraperitoneal) administration in rodent models, KPV is rapidly absorbed into the systemic circulation, with maximal plasma concentrations reported within 15 to 30 minutes of injection. ^[3] The bioavailability by the subcutaneous route is estimated to be high (above 80%) based on area-under-the-curve comparisons with intravenous data, which is consistent with the low molecular weight facilitating diffusion across the extracellular matrix.

Oral bioavailability of free KPV is substantially lower due to gastric acid hydrolysis and proteolytic degradation by pancreatic enzymes in the lumen. Literature estimates of oral bioavailability for free tripeptide range from 5 to 15%, with the proline residue providing partial protection compared with sequences susceptible to prolyl endopeptidase. ^[5] However, transport via PepT1 in the small intestinal epithelium can deliver intact KPV directly into enterocytes, and the compound may exert local effects on the intestinal mucosa even when systemic exposure is limited.

Distribution

Plasma protein binding for KPV has not been formally characterized in published literature, a gap that makes precise free-fraction calculations impossible. Given the compound's small size and basic Lys residue, moderate protein binding (20-40%) is anticipated but not confirmed. Distribution into the intestinal wall after both parenteral and oral delivery has been confirmed by radioisotope tracing in rodent studies, and the compound partitions preferentially into inflamed tissue relative to normal tissue, consistent with enhanced permeability in inflamed vasculature. ^[8]

Metabolism and Elimination

KPV is metabolized by aminopeptidases and carboxypeptidases in plasma and tissue, yielding individual amino acids that enter normal metabolic pools. No toxic metabolites have been identified in published research, and the end products (Lys, Pro, Val) are endogenous nutrients. ^[4] Plasma half-life in rodent models has been measured at approximately 20 to 30 minutes for free tripeptide following intravenous administration, extending to 45 to 75 minutes following subcutaneous administration (reflecting absorption-rate-limited kinetics). Renal excretion of intact KPV accounts for a minor fraction of elimination due to glomerular filtration of the small molecule, with the majority being metabolized.

Pharmacokinetic Implications for Experimental Design

The short plasma half-life of KPV has direct implications for in vivo study design. Single-injection protocols will produce a narrow window of peak exposure, and researchers should time tissue harvesting and endpoint measurements relative to the predicted Tmax. For sustained anti-inflammatory effects in rodent models, most published studies use once-daily or twice-daily dosing schedules, which produce intermittent rather than continuous receptor engagement. Whether continuous exposure (achievable with osmotic minipumps) produces different efficacy outcomes than intermittent injection has not been systematically compared for KPV specifically, though the question is relevant to mechanism-of-action studies. ^[11]

The enhanced permeability and retention effect in inflamed tissue may effectively extend the functional exposure time at sites of pathology beyond what plasma half-life would predict, a phenomenon relevant to interpreting the in vivo colitis data where treatment effects appear sustained beyond the pharmacokinetic window of a single dose.

Purity and Verification

What a CoA Should Contain

A reliable certificate of analysis (CoA) for research-grade KPV should include the following minimum information: HPLC chromatogram with peak area percentage (purity should be stated as ≥98% by area normalization), retention time with column and gradient conditions specified, mass spectrometry confirmation of the molecular ion (expected [M+H]+ at 372.2 Da for the free-acid form), lot number, manufacturing date, and storage recommendations.

Any CoA that does not include a chromatogram, or that reports purity without specifying the analytical method, should be treated with skepticism. Some vendors report purity by UV absorbance at a single wavelength, which can overestimate purity if impurities have low extinction coefficients. Mass spectrometry confirmation is the minimum standard for verifying that the correct compound was synthesized; HPLC alone cannot rule out isomeric impurities with the same molecular weight.

Independent Verification Approaches

Researchers receiving a new KPV lot can perform straightforward in-house verification using a benchtop LC-MS system. A C18 reverse-phase column with a water-acetonitrile-TFA gradient will resolve KPV from common synthetic impurities including Lys-Pro dipeptide (MW 243.3), Pro-Val dipeptide (MW 214.3), and deletion sequences. The expected retention time for KPV under standard conditions is between 4 and 8 minutes depending on gradient steepness, eluting substantially earlier than most protecting-group impurities from SPPS synthesis.

For cell-culture applications, endotoxin testing using a Limulus Amebocyte Lysate (LAL) assay is strongly recommended, particularly for immunological studies where LPS contamination from bacterial expression or synthetic process residues could independently activate NF-kB and confound results. Accepted thresholds for cell culture applications are generally below 1 EU/mg peptide. For in vivo animal studies, the threshold is typically below 5 EU/kg body weight per injection.

Amino acid analysis can confirm composition but does not confirm sequence; mass spectrometry with fragmentation (MS/MS) is required to confirm the sequence of a tripeptide, though this level of verification is typically reserved for internal QC rather than every researcher sourcing the compound.

Stability During Research Workflows

Lyophilized KPV is stable at -20°C for at least 24 months when stored correctly in sealed vials with desiccant. Reconstituted solutions at concentrations above 1 mg/mL in bacteriostatic water maintain stability at 4°C for approximately 7 days with minimal degradation, as assessed by HPLC. Freeze-thaw cycling degrades KPV solutions; researchers should prepare single-use aliquots after initial reconstitution rather than repeatedly thawing and refreezing the master stock. Exposure to light, particularly UV, can promote oxidative modification of the Lys side chain; brown or amber storage vials are recommended.

Dosage and Reconstitution

Literature-Reported Research Doses

Published preclinical research has used a range of KPV concentrations depending on the experimental system and delivery route. The following is a summary of doses from the studies reviewed, presented for research planning purposes only.

In murine colitis models (DSS or TNBS): literature-reported doses range from 0.3 to 0.5 mg/kg per day via subcutaneous, intraperitoneal, or oral-nanoparticle routes. ^[13] In rat wound healing models: subcutaneous peri-wound dosing at approximately 0.2 to 0.4 mg/kg per day. In cell culture (macrophage and epithelial cell lines): 10 nM to 1 microM, with most published studies reporting optimal NF-kB inhibition between 100 nM and 500 nM.

For detailed calculation guidance on converting vial content to working concentrations in these experimental contexts, see our dosage calculation guide.

Reconstitution Worked Examples

Example 1, Cell Culture Stock Solution (1 mM)

A researcher needs a 1 mM stock solution of KPV for a macrophage cytokine inhibition assay. The molecular weight of KPV free acid is 371.47 g/mol. To prepare 1 mL of 1 mM solution: mass required = 0.001 mol/L x 0.001 L x 371.47 g/mol = 0.000371 g = 0.371 mg. From a 10 mg vial, dissolve the entire vial in sterile water to 10 mg/mL, then dilute 37.1 microliters into 962.9 microliters of cell culture medium to yield 1 mM in 1 mL total volume. From this 1 mM stock, prepare working concentrations (100 nM = 1:10,000 dilution; 500 nM = 1:2,000 dilution) in assay buffer.

Example 2, In Vivo Subcutaneous Injection (0.5 mg/kg in 25g Mouse)

A researcher is replicating the DSS colitis literature protocol. Target dose: 0.5 mg/kg. Animal weight: 25 g (0.025 kg). Total dose required: 0.5 x 0.025 = 0.0125 mg = 12.5 micrograms. A convenient formulation is 0.5 mg/mL in 0.9% saline (pH adjusted to 6.5-7.0), yielding an injection volume of 25 microliters, which is appropriate for subcutaneous delivery in mice. From a 10 mg vial reconstituted to 10 mg/mL, dilute 1 part into 19 parts saline to yield 0.5 mg/mL working solution.

Example 3, Transwell Barrier Integrity Assay (100 nM Treatment)

A researcher is running a Caco-2 TEER assay in a 12-well Transwell plate (1 mL apical volume per well). Working concentration: 100 nM. From a 1 mM stock prepared as in Example 1, add 0.1 microliters per mL of assay medium (1:10,000 dilution). Since pipetting 0.1 microliters accurately is not reliable with standard pipettes, prepare an intermediate 10 microM stock (1:100 dilution of the 1 mM stock), then add 10 microliters of the 10 microM intermediate to 990 microliters of apical medium (final: 100 nM).

For full reconstitution protocols, sterility technique, and aliquoting recommendations, consult our comprehensive peptide reconstitution guide.

Side Effects and Safety

Preclinical Safety Observations

Published preclinical studies have consistently reported an absence of overt toxicity signals at the research doses used in colitis, wound healing, and in vitro models. In rodent studies using KPV at doses up to 1 mg/kg for periods of 5 to 14 days, no significant changes in body weight, liver enzyme levels, hematological parameters, or gross organ histology were observed in KPV-treated animals compared with vehicle controls. ^[13]

The parent peptide alpha-MSH is an endogenous signaling molecule with a well-characterized physiological role, and KPV's derivation from this sequence suggests a degree of endogenous compatibility. However, the absence of observed toxicity in short-duration rodent studies does not constitute a safety clearance for any use outside of approved laboratory research, and does not provide information about chronic exposure effects, reproductive toxicity, or any human-specific safety considerations.

Immunogenicity

As a three-amino-acid sequence composed entirely of proteinogenic amino acids, KPV has an extremely low theoretical immunogenicity risk. Tripeptides are generally too small to form T-cell epitopes or serve as B-cell antigens without hapten conjugation. No published studies have reported KPV-specific antibody formation in animal models following repeated administration. ^[4] This is a practical advantage for long-duration in vivo experiments where anti-drug antibodies can confound dose-response relationships.

Potential Off-Target Effects

KPV's melanocortin receptor binding, even at the relatively low affinity of the tripeptide versus the full alpha-MSH sequence, raises the question of pigmentation effects. MC1R stimulation in melanocytes increases eumelanin synthesis, and theoretical repeated KPV administration could influence coat color in pigmentation-sensitive rodent strains. Published studies have not systematically examined this endpoint. Researchers using KPV in experiments where melanocyte function is a study variable should be aware of this potential confound.

MC3R is also expressed in the hypothalamus and plays a role in energy balance. No KPV studies have reported significant body weight or food intake changes at standard research doses, suggesting that hypothalamic MC3R engagement is minimal at these concentrations, but this has not been rigorously characterized. ^[7]

Research Handling Safety

Standard laboratory personal protective equipment (gloves, lab coat, eye protection) is appropriate when handling lyophilized KPV powder, primarily to prevent inhalation of fine powder and skin sensitization. KPV does not present known chemical hazards beyond standard peptide handling precautions. Disposal should follow institutional protocols for research chemicals.

How It Compares

KPV sits within a broader category of research peptides with anti-inflammatory, gut-barrier, and wound-healing activities. Understanding how it compares with closely related compounds helps researchers select the most appropriate tool for a given experimental question.

KPV versus BPC-157

BPC-157 (Body Protective Compound-157) is a 15-amino-acid synthetic pentadecapeptide derived from a gastric mucosa-stabilizing protein, and it represents the most commonly studied research peptide in the gut-healing and tissue-repair categories. ^[15] The two compounds share a research focus on intestinal inflammation and wound healing, but their mechanisms diverge substantially. BPC-157 primarily acts through angiogenic pathways (VEGFR2 upregulation, nitric oxide production) and FAK-dependent cell migration, while KPV acts through cytokine suppression and barrier protein upregulation.

In a research design context, this means KPV is a more targeted anti-inflammatory tool while BPC-157 has broader tissue-regenerative activity. For studies specifically interrogating cytokine-mediated mucosal damage, KPV's more focused NF-kB and inflammasome mechanism may be preferable. For studies requiring both vascular and inflammatory components of healing to be addressed, BPC-157 provides a broader toolkit. The two compounds have not been formally studied together in combination, which is an open research opportunity.

KPV versus Alpha-MSH

The comparison between KPV and its parent peptide alpha-MSH is important for researchers choosing between the fragment and the full sequence. Alpha-MSH engages all five melanocortin receptor subtypes, produces robust pigmentation effects through MC1R on melanocytes, and has hypothalamic effects on energy balance through MC3R and MC4R that KPV does not appear to replicate at standard research doses. ^[1] For studies specifically investigating anti-inflammatory signaling where pigmentation or metabolic confounds are undesirable, KPV offers greater experimental specificity. For studies that require the full melanocortin receptor profile to be engaged, the intact alpha-MSH sequence is more appropriate.

KPV versus GHK-Cu

Glycine-Histidine-Lysine copper (GHK-Cu) is another tripeptide with documented activity in wound healing and tissue remodeling, primarily through TGF-beta pathway modulation and copper-mediated enzymatic activation. ^[16] Unlike KPV, GHK-Cu's mechanism depends critically on copper coordination, introducing a metal-dependent variable that can be confounded by copper availability in culture media. KPV's mechanism does not involve transition metal coordination, making it more tractable in standard cell culture conditions. For skin and fibroblast research specifically, GHK-Cu has a substantial and in some respects more developed literature base; for intestinal and macrophage research, KPV's evidence base is stronger.

Where to Buy

Apollo Peptide Sciences supplies KPV 10mg through our reviewed vendor listing. Before purchasing any research peptide, researchers should verify that the supplier provides lot-specific CoAs with HPLC chromatograms and mass spectrometry data, has a documented quality management process, and can provide endotoxin test results on request. See our supplier evaluation guide for a structured framework for vetting research peptide vendors.

The Apollo Peptide Sciences KPV 10mg is listed in our full product review at /product/kpv-10mg, where vendor-specific CoA data, independent verification notes, and shipping logistics are detailed. Researchers comparing multiple suppliers for KPV should review our supplier comparison page for a side-by-side analysis of quality metrics across vendors currently offering this compound.

At $50.00 for a 10 mg vial, the per-milligram cost is $5.00. This is competitive relative to the broader tripeptide research peptide market, where prices range from $3.00 to $10.00 per milligram for verified research-grade product. Bulk pricing and multi-vial discounts, where available, are detailed on the vendor page.

Open Research Questions

KPV has an unusually coherent mechanistic story for a research peptide, but several important questions remain unresolved in the published literature.

The relative contribution of MC1R-mediated versus receptor-independent signaling to KPV's anti-inflammatory effects is not settled. Most studies either use non-specific inflammatory stimuli that engage multiple pathways, or use pharmacological antagonists with imperfect selectivity. Clean genetic approaches using MC1R-null cell lines or CRISPR-knockout intestinal organoids would provide much more definitive mechanistic clarity.

The question of optimal delivery system for intestinal research is only partially answered. The Bhatt (2018) nanoparticle data strongly support encapsulation for oral delivery, but the nanoparticle formulation itself introduces variables (polymer chemistry, surface charge, particle size) that affect biodistribution and inflammatory responses independently. A systematic comparison of free KPV, liposomal KPV, polymer-NP KPV, and KPV-hydrogel formulations in the same colitis model has not been published.

KPV's effects in neuroinflammation models are understudied relative to its gut and skin data. Given that alpha-MSH exerts central anti-inflammatory effects and that MC1R and MC3R are expressed in microglia, the tripeptide's activity in brain injury, neuroinflammation, and blood-brain barrier integrity models warrants systematic investigation. ^[17]

The synergy or antagonism between KPV and existing anti-inflammatory agents (5-aminosalicylates, corticosteroids, biologics) has not been characterized, which is relevant both for translational research planning and for understanding mechanism redundancy.

Finally, the absence of formal human pharmacokinetic or safety data means the translational gap remains entirely uncharted. Phase I pharmacokinetic studies in healthy volunteers, which would require appropriate regulatory filings, do not exist in the public literature. This gap is the single most important limitation on the compound's translational relevance.

FAQ